We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth [Yahoo! Finance]
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: Yahoo! Finance
For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com? Given this risk, we thought we'd take a look at whether Atossa Therapeutics NASDAQ:ATOS ) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Atossa Therapeutics last reported its December 2024 balance sheet in March 2025, it had zero debt and cash worth US$71m. Importantly
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer SymposiumPR Newswire
- Atossa gains on Rare Pediatric Disease status for Duchenne asset [Seeking Alpha]Seeking Alpha
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular DystrophyPR Newswire
ATOS
Sec Filings
- 12/12/25 - Form PRE
- 12/4/25 - Form 8-K
- 11/12/25 - Form 10-Q
- ATOS's page on the SEC website